Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial is studying how well selumetinib works in treating patients with
relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.